UCB announced that the FDA has set the Prescription Drug User Fee Act (PDUFA) date for UCB’s Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis at October 15, 2021.
A new, easy-to-use EEG electrode set for the measurement of the electrical activity of the brain was developed in a...
Alnylam, the leading RNAi therapeutics company, announced that the FDA has set a date of September 13, 2023 for the meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the supplemental New Drug Application for patisiran, an investigational treatment for the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis
axter International Inc. announced that the peer-reviewed journal Blood Purification published a supplemental issue sponsored by Baxter that features real-world...
Background: Most totally blind people have non-24-hour sleep–wake disorder (non-24), a rare circadian rhythm disorder caused by an inability of light to reset their circadian pacemaker.
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase III RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis
The scope of the guidelines is limited to current diagnostic tools, management and service set-up and delivery to facilitate delivery of optimal clinical care pathways and management for patients with RVO.
Recro Pharma, Inc. announced that the FDA has set a PDUFA goal date of 24 March 2019 for its decision...
Novartis announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC).
Becton, Dickinson and Company a leading global medical technology company announced the FDA 510(k) clearance and European CE marking for...